Athira Pharma to Present Preclinical Data Highlighting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND
11/28/2022 - 07:00 AM
HGF/MET small molecule positive modulator provides neuroprotection and improves motor and nerve function in a TDP-43 mouse model of ALS
BOTHELL, Wash., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced it will present preclinical data highlighting the therapeutic potential of ATH-1105, a small molecule positive modulator of the HGF/MET neurotrophic system, in amyotrophic lateral sclerosis (ALS), at the Motor Neurone Disease Association’s 33rd International Symposium on ALS/MND being held virtually from December 6-9, 2022.
Presentation Details:
Title: Small Molecule Hepatocyte Growth Factor (HGF)/MET Positive Modulator ATH-1105 is Neuroprotective in the TDP-43 Mouse Model of Amyotrophic Lateral Sclerosis Format: PosterPoster Reference: TST-05Presentation Theme: Theme 07 – Pre-clinical Therapeutic StrategiesPresenter: Kevin Church, Ph.D., EVP, ResearchTime/Date: Live Poster Session A, Tuesday, December 6, 2022, 5:05 PM - 6:35 PM Pacific Time
The presentation will be available on the Scientific Publications & Presentations w ww.at hira.com .
About Athira Pharma, Inc. www.athira.com . You can also follow Athira on Facebook , LinkedIn and @athirapharma on Twitter and Instagram .
Investor & Media Contact
ATHA Rankings
#4750 Ranked by Stock Gains
ATHA Stock Data
Industry
Biological Product (except Diagnostic) Manufacturing
Sector
Manufacturing
Tags
Commercial Services, Miscellaneous Commercial Services, Health Technology, Biotechnology, Manufacturing, Medicinal and Botanical Manufacturing
About ATHA
m3 biotechnology is an innovative therapeutics company that has a novel platform of disease-modifying regenerative small molecules, particularly relevant to neurodegenerative diseases. the lead compound modifies growth-factor systems, where the activation is expected to stop disease progression and even restore lost function. the company’s research has been funded by the alzheimer’s drug discovery foundation, washington’s life sciences discovery fund, w fund, wrf capital, dolby family ventures and other private investors. where current and emerging therapies are focused primarily on disease symptoms and improving the quality of life of patients suffering from disease, m3 differentiates itself from the competition by addressing the neurodegenerative process, providing a cost-effective solution and feasible delivery mechanism. our strategy is to leverage our patented and proprietary technologies to develop small molecule modulators with a primary focus on altering the course of alzheimer
